Four Stem-Cell Stocks With Promise

NEW YORK (TheStreet) — Fate Therapeutics (FATE) is developing several small molecules that modulate umbilical-cord stem cells. Reni Benjamin, a biotech analyst at Raymond James Financial, said. The company’s shares, which are already up over 40% this year …

[Read the full article here]

Comments are closed.